Molecular characterization of Chilean patients with a clinical diagnosis of Noonan syndrome
Author
dc.contributor.author
Rodríguez, Fernando A.
Author
dc.contributor.author
Unanue Morales, Nancy
es_CL
Author
dc.contributor.author
Hernández Cárdenas, María Isabel
es_CL
Author
dc.contributor.author
Heath, Karen E.
es_CL
Author
dc.contributor.author
Cassorla Goluboff, Fernando
es_CL
Admission date
dc.date.accessioned
2014-12-11T20:08:15Z
Available date
dc.date.available
2014-12-11T20:08:15Z
Publication date
dc.date.issued
2014
Cita de ítem
dc.identifier.citation
J Pediatr Endocr Met 2014; 27(3-4): 305–309
en_US
Identifier
dc.identifier.other
DOI 10.1515/jpem-2013-0176
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/129352
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Background: Noonan syndrome (NS) is an autosomal
dominant syndrome characterized by typical dysmorphic
features, cardiac anomalies as well as postnatal growth
retardation, and is associated with Ras-MAPK pathway
gene mutations. The purpose of this study was to improve
the diagnosis of Chilean patients with suspected NS
through molecular analysis.
Methods: We screened 18 Chilean patients with a clinical
diagnosis of NS for mutations in PTPN11 by high resolution
melting (HRM) and subsequent sequencing.
Results: Three PTPN11 missense mutations were detected
in 22% of analyzed patients. Of these, two (c.181G > A and
c.1510A > G) were previously reported and one was the novel
substitution c.328G > A (p.E110K) affecting the linker stretch
between the N-SH2 and C-SH2 domains of SHP-2 protein.
Conclusion: Molecular studies confirmed the clinical diagnosis
of NS in 4 of 18 patients, which provided support for
therapeutic decisions and improved genetic counseling
for their families.